Inmune Bio (INMB) Debt Ratio (2021 - 2024)

Inmune Bio (INMB) posted Debt Ratio of 0.38 for Q4 2024, up 300.73% sequentially from 0.09 in Q3 2024, and up 117.84% YoY from 0.17 in Q1 2024.

Inmune Bio (INMB) Debt Ratio (2021 - 2024) Analysis & Trends

Inmune Bio has reported Debt Ratio for 4 years, with the latest figure at 0.38 in Q4 2024.

Quarterly Debt Ratio rose 117.84% year-over-year to 0.38 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.38 (up 117.84% YoY) and the FY2024 annual result came in at 0.38, up 117.84% from the prior year.
Debt Ratio grew to 0.38 in Q4 2024 per INMB's latest filing, from 0.09 in the prior quarter.
Over five years, Debt Ratio peaked at 0.38 in Q4 2024 and troughed at 0.09 in Q3 2024.
A 4-year average of 0.2 and a median of 0.18 in 2022 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 117.84% in 2024, down 52.07% in 2024.
Over 4 years, Debt Ratio stood at 0.14 in 2021, then increased by 24.21% to 0.18 in 2022, then declined by 3.13% to 0.17 in 2023, then jumped by 117.84% to 0.38 in 2024.
According to Business Quant data, Debt Ratio over the past three periods registered 0.38, 0.09, and 0.19 for Q4 2024, Q3 2024, and Q2 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.65 Bn	130.80 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.93 Bn	77.94 Bn	3.93 Bn	0.05
3	Argenx Se	64.84 Bn	59.66 Bn	1.37 Bn	-
4	Moderna	57.38 Bn	52.25 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.54 Bn	28.23 Bn	992.69 Mn	-
7	BioNTech SE	27.72 Bn	9.33 Bn	668.28 Mn	0.03
8	Insmed	27.49 Bn	26.33 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.47
10	Inmune Bio	61.32 Mn	42.91 Mn	-	-

Download Data